PMID- 26782508
OWN - NLM
STAT- MEDLINE
DCOM- 20161219
LR  - 20161230
IS  - 1676-5680 (Electronic)
IS  - 1676-5680 (Linking)
VI  - 14
IP  - 4
DP  - 2015 Dec 29
TI  - Correlation between serum YKL-40 levels and albuminuria in type 2 diabetes.
PG  - 18596-603
LID - 10.4238/2015.December.28.7 [doi]
AB  - We explored the correlation between serum YKL-40 levels and albuminuria in type 2 
      diabetes mellitus (T2DM) and its clinical significance. This study used a 
      cross-sectional survey method. According to the American Diabetes Association 
      2007 Clinical Practice Recommendations, 738 patients with T2DM were divided into 
      three groups: a normoalbuminuria group [albumin-to-creatinine ratio (ACR) <30 
      mug/mg, N = 360], a microalbuminuria group (ACR 30-300 mug/mg, N = 246), and a 
      macroalbuminuria group (ACR >/= 300 mug/mg, N = 332). The serum YKL-40 levels were 
      determined by a quantitative sandwich enzyme-linked immunosorbent assay in all 
      the cases and in 210 control subjects. Serum YKL-40 levels were significantly 
      higher in the T2DM group vs the control group (P < 0.05), the macroalbuminuria 
      group vs the microalbuminuria group (P < 0.05), and the microalbuminuria group vs 
      the normoalbuminuria group (P < 0.05). Serum YKL-40 levels correlated with ACR in 
      all participants. Significant correlation of YKL-40 was found with ACR, 2-h 
      plasma glucose, glycated hemoglobin, fasting blood glucose, homeostatic model 
      assessment of insulin resistance index, systolic blood pressure, duration, 
      diastolic blood pressure, age, triglycerides, and high-density lipoprotein 
      cholesterol (r-values: 0.713, 0.524, 0.515, 0.467, 0.438, 0.409, 0.407, 0.374, 
      0.112, 0.097, and -0.123, respectively). ACR correlated with serum YKL-40 levels 
      (Beta = 0.555, P < 0.001). YKL-40 may be involved in the occurrence and 
      development of diabetic nephropathy and would be useful as a new marker for the 
      disease.
FAU - Han, J Y
AU  - Han JY
AD  - The Geriatrics Department, The First Affiliated Hospital of China Medical 
      University, Shenyang, Liaoning Province, China.
FAU - Ma, X Y
AU  - Ma XY
AD  - The Geriatrics Department, The First Affiliated Hospital of China Medical 
      University, Shenyang, Liaoning Province, China.
FAU - Yu, L J
AU  - Yu LJ
AD  - The Geriatrics Department, The First Affiliated Hospital of China Medical 
      University, Shenyang, Liaoning Province, China.
FAU - Shao, Y
AU  - Shao Y
AD  - The Endocrine Department, The First Affiliated Hospital of China Medical 
      University, Shenyang, Liaoning Province, China.
FAU - Wang, Q Y
AU  - Wang QY
AD  - The Endocrine Department, The First Affiliated Hospital of China Medical 
      University, Shenyang, Liaoning Province, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151229
PL  - Brazil
TA  - Genet Mol Res
JT  - Genetics and molecular research : GMR
JID - 101169387
RN  - 0 (Biomarkers)
RN  - 0 (CHI3L1 protein, human)
RN  - 0 (Chitinase-3-Like Protein 1)
SB  - IM
MH  - Albuminuria/diagnosis/*etiology
MH  - Biomarkers
MH  - Chitinase-3-Like Protein 1/*blood
MH  - Diabetes Mellitus, Type 2/*blood/*complications/diagnosis
MH  - Diabetic Nephropathies/diagnosis/urine
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
EDAT- 2016/01/20 06:00
MHDA- 2016/12/20 06:00
CRDT- 2016/01/20 06:00
PHST- 2016/01/20 06:00 [entrez]
PHST- 2016/01/20 06:00 [pubmed]
PHST- 2016/12/20 06:00 [medline]
AID - gmr6377 [pii]
AID - 10.4238/2015.December.28.7 [doi]
PST - epublish
SO  - Genet Mol Res. 2015 Dec 29;14(4):18596-603. doi: 10.4238/2015.December.28.7.